A detailed history of Morgan Jess S & CO Inc transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Morgan Jess S & CO Inc holds 78,895 shares of AXSM stock, worth $7.16 Million. This represents 3.06% of its overall portfolio holdings.

Number of Shares
78,895
Previous 104,889 24.78%
Holding current value
$7.16 Million
Previous $4.02 Million 12.37%
% of portfolio
3.06%
Previous 4.17%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 21, 2022

SELL
$36.06 - $69.85 $937,343 - $1.82 Million
-25,994 Reduced 24.78%
78,895 $3.52 Million
Q2 2022

Jul 18, 2022

SELL
$21.74 - $46.75 $49,958 - $107,431
-2,298 Reduced 2.14%
104,889 $4.02 Million
Q1 2022

May 16, 2022

SELL
$23.7 - $41.39 $173,910 - $303,719
-7,338 Reduced 6.41%
107,187 $4.44 Million
Q4 2021

Jan 27, 2022

BUY
$30.7 - $43.36 $33,616 - $47,479
1,095 Added 0.97%
114,525 $4.33 Million
Q3 2021

Nov 09, 2021

BUY
$19.91 - $68.26 $907,796 - $3.11 Million
45,595 Added 67.21%
113,430 $3.74 Million
Q2 2021

Nov 30, 2021

BUY
$50.63 - $73.5 $768,411 - $1.12 Million
15,177 Added 28.82%
67,835 $4.58 Million
Q1 2021

Nov 30, 2021

BUY
$55.91 - $81.44 $457,902 - $666,993
8,190 Added 18.42%
52,658 $2.98 Million
Q4 2020

Nov 30, 2021

BUY
$66.31 - $86.52 $361,389 - $471,534
5,450 Added 13.97%
44,468 $3.62 Million
Q3 2020

Nov 29, 2021

SELL
$68.34 - $85.84 $21,185 - $26,610
-310 Reduced 0.79%
39,018 $2.78 Million
Q2 2020

Nov 29, 2021

SELL
$49.87 - $98.69 $153,300 - $303,373
-3,074 Reduced 7.25%
39,328 $3.24 Million
Q1 2020

Nov 29, 2021

BUY
$41.2 - $101.31 $1.52 Million - $3.74 Million
36,902 Added 670.95%
42,402 $2.5 Million
Q4 2019

Nov 19, 2021

BUY
$16.71 - $106.24 $91,905 - $584,320
5,500 New
5,500 $568,000

Others Institutions Holding AXSM

About Axsome Therapeutics, Inc.


  • Ticker AXSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,878,000
  • Market Cap $3.89B
  • Description
  • Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...
More about AXSM
Track This Portfolio

Track Morgan Jess S & CO Inc Portfolio

Follow Morgan Jess S & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Jess S & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Jess S & CO Inc with notifications on news.